NCT05348889 - First-in-Human (FIH) Trial of 1A46 in Subjects with Advanced CD20 And/or CD19 Positive B-cell Hematologic Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 30, 2022

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2024

Conditions

Non-Hodgkin's Lymphoma (disorder)Acute Lymphoid Leukemia, Disease (disorder)

Interventions

DRUG

1A46 Injection

Participants will receive IV 1A46 weekly for Cycles 1-8, then every 3 weeks (Q3W) for Cycles 9-16 (21 days/cycle).

Trial Locations (5)

Yale New Haven Hospital, New Haven

Norton Cancer Institute, Louisville

UPMC CancerCenter, Pittsburgh

The University of Texas MD Anderson Cancer Center, Houston

Froedtert & the Medical College of Wisconsin Froedtert Hospital, Milwaukee